Thousand Oaks – – October 29, 2026 -- Amgen (NASDAQ:AMGN) will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of U.S. financial markets.

Amgen schedules investor call for 4:30 p.m. ET with CEO Bradway

The earnings release will be followed by a conference call with the investment community at 4:30 p.m. ET. Robert A. Bradway, chairman and chief executive officer, will participate alongside other members of Amgen's senior management team.

Thousand Oaks – October 28, 2026 -- Amgen's Board of Directors declared a fourth-quarter 2026 dividend of $2.52 per share, the company (NASDAQ: AMGN) announced.

Amgen sets December 11 payment date for Q4 dividend

The dividend will be paid on December 11, 2026, to all stockholders of record as of the close of business on November 20, 2026.

Thousand Oaks – October 28, 2026 -- Amgen's dazodalibep reduced systemic disease activity in Sjögren's disease patients by 5.6 points on the ESSDAI scale at Week 48 in the Phase 3 OASIZ-301 trial, against 3.8 points for placebo. The company will present the late-breaking data at the American College of Rheumatology (ACR) Convergence 2026.

Thousand Oaks -- Amgen (NASDAQ:AMGN) will hold an investor webcast on Saturday, October 24, 2026, at 11:30 a.m. PT to discuss its oncology portfolio and selected data presented at the European Society of Medical Oncology Congress (ESMO) 2026.

Two senior executives lead Amgen's ESMO 2026 investor call

Murdo Gordon, executive vice president of Global Markets and Policy, and Jean-Charles Soria, senior vice president of oncology within Global Development, will lead the session. Other members of Amgen's management team will also take part.

San Diego – September 30, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has appointed James "Jim" Daly to its Board of Directors, returning a veteran biopharmaceutical commercial executive to help steer the company's drug-delivery technology expansion.

Thousand Oaks, Calif. – September 07, 2026 -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026.

Amgen's CFO and top medical and marketing executives will address investors

Thomas Dittrich, executive vice president and chief financial officer, Paul Burton, M.D., Ph.D., senior vice president and chief medical officer, and Kave Niksefat, senior vice president of Global Marketing and Access, will represent Amgen at the conference.

MUNICH, Germany -- August 31, 2026 -- Amgen's Repatha (evolocumab) reduced all-cause mortality by 20% in high-risk patients who had never suffered a heart attack or stroke, according to a pre-specified analysis of the Phase 3 VESALIUS-CV trial presented at the European Society of Cardiology Congress 2026 and published simultaneously in Circulation.

THOUSAND OAKS, Calif. -- September 01, 2026 -- Amgen said its cholesterol drug Repatha reduced the risk of death by 20% among more than 12,000 high-risk adults who had not yet suffered a heart attack or stroke, based on a pre-specified analysis of the Phase 3 VESALIUS-CV trial. The company presented the data in a late-breaking session at the European Society of Cardiology Congress 2026 in Munich, Germany, and published the findings simultaneously in Circulation.